{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:38:07Z","timestamp":1794883087093,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Some patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) go on to experience post-COVID-19 condition or long COVID. Preliminary findings have given rise to the theory that long COVID may be due in part to a deranged immune response. In this study, we assess whether there is an association between SARS-CoV-2 infection and the incidence of immune-mediated inflammatory diseases (IMIDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Matched cohort study using primary care electronic health record data from the Clinical Practice Research Datalink Aurum database. The exposed cohort included 458,147 adults aged 18\u00a0years and older with a confirmed SARS-CoV-2 infection and no prior diagnosis of IMIDs. They were matched on age, sex, and general practice to 1,818,929 adults with no diagnosis of confirmed or suspected SARS-CoV-2 infection. The primary outcome was a composite of any of the following IMIDs: autoimmune thyroiditis, coeliac disease, inflammatory bowel disease (IBD), myasthenia gravis, pernicious anaemia, psoriasis, rheumatoid arthritis (RA), Sjogren\u2019s syndrome, systemic lupus erythematosus (SLE), type 1 diabetes mellitus (T1DM), and vitiligo. The secondary outcomes were each of these conditions separately. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for the primary and secondary outcomes, adjusting for age, sex, ethnic group, smoking status, body mass index, relevant infections, and medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six hundred and nighty six (0.15%) and 2230 (0.12%) patients in the exposed and unexposed cohort developed an IMID during the follow-up period over 0.29 person-years, giving a crude incidence rate of 4.59 and 3.65 per 1000 person-years, respectively. Patients in the exposed cohort had a 22% increased risk of developing an IMID, compared to the unexposed cohort (aHR 1.22, 95% CI 1.12 to 1.33). The incidence of three IMIDs was significantly associated with SARS-CoV-2 infection. These were T1DM (aHR 1.56, 1.09 to 2.23), IBD (aHR 1.36, 1.18 to 1.56), and psoriasis (1.23, 1.05 to 1.42).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SARS-CoV-2 was associated with an increased incidence of IMIDs including T1DM, IBD and psoriasis. However, these findings could be potentially due to ascertainment bias. Further research is needed to replicate these findings in other populations and to measure autoantibody profiles in cohorts of individuals with COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-023-03049-5","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T06:01:53Z","timestamp":1695276113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care"],"prefix":"10.1186","volume":"21","author":[{"given":"Umer","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradhaa","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wraith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet M.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Ghokale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnarajah","family":"Nirantharakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamil","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"issue":"3","key":"3049_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141\u201354.","journal-title":"Nat Rev Microbiol"},{"key":"3049_CR2","unstructured":"WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int. Accessed 19 Apr 2022."},{"issue":"2","key":"3049_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/BOR.0000000000000776","volume":"33","author":"Y Liu","year":"2021","unstructured":"Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155\u201362.","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"3049_CR4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(21)00333-9","volume":"21","author":"MJ Burke","year":"2021","unstructured":"Burke MJ, del Rio C. Long COVID has exposed medicine\u2019s blind-spot. Lancet Infect Dis. 2021;21(8):1062\u20134.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"3049_CR5","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","volume":"22","author":"JB Soriano","year":"2022","unstructured":"Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102\u20137.","journal-title":"Lancet Infect Dis"},{"key":"3049_CR6","unstructured":"National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the longterm effects of COVID-19 NICE; 2022."},{"issue":"9","key":"3049_CR7","doi-asserted-by":"publisher","first-page":"e1003773","DOI":"10.1371\/journal.pmed.1003773","volume":"18","author":"M Taquet","year":"2021","unstructured":"Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773.","journal-title":"PLoS Med"},{"key":"3049_CR8","volume-title":"Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021","author":"D Ayoubkhani","year":"2021","unstructured":"Ayoubkhani D, Gaughan C. Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. Newport: Office for National Statistics; 2021."},{"issue":"10302","key":"3049_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0140-6736(21)01900-0","volume":"398","author":"L The","year":"2021","unstructured":"The L. Understanding long COVID: a modern medical challenge. Lancet. 2021;398(10302):725.","journal-title":"Lancet"},{"issue":"7866","key":"3049_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","volume":"595","author":"EY Wang","year":"2021","unstructured":"Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283\u20138.","journal-title":"Nature"},{"issue":"570","key":"3049_CR11","doi-asserted-by":"publisher","first-page":"eabd3876","DOI":"10.1126\/scitranslmed.abd3876","volume":"12","author":"Y Zuo","year":"2020","unstructured":"Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876.","journal-title":"Sci Transl Med"},{"issue":"5","key":"3049_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","volume":"185","author":"Y Su","year":"2022","unstructured":"Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-95.e20.","journal-title":"Cell"},{"key":"3049_CR13","doi-asserted-by":"publisher","first-page":"645013","DOI":"10.3389\/fimmu.2021.645013","volume":"12","author":"K-T Tang","year":"2021","unstructured":"Tang K-T, Hsu B-C, Chen D-Y. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 2021;12:645013.","journal-title":"Front Immunol"},{"key":"3049_CR14","doi-asserted-by":"publisher","first-page":"102592","DOI":"10.1016\/j.jaut.2020.102592","volume":"117","author":"L Novelli","year":"2021","unstructured":"Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 \u2013 a systematic review of the literature. J Autoimmun. 2021;117:102592.","journal-title":"J Autoimmun"},{"issue":"10","key":"3049_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/23744235.2021.1924397","volume":"53","author":"SJ Yong","year":"2021","unstructured":"Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737\u201354.","journal-title":"Infect Dis"},{"issue":"5","key":"3049_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12026-020-09152-6","volume":"68","author":"D Kanduc","year":"2020","unstructured":"Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res. 2020;68(5):310\u20133.","journal-title":"Immunol Res"},{"issue":"1","key":"3049_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","volume":"128","author":"PB Burns","year":"2011","unstructured":"Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305\u201310.","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"3049_CR18","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/ije\/dyz034","volume":"48","author":"A Wolf","year":"2019","unstructured":"Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48(6):1740-g.","journal-title":"Int J Epidemiol."},{"issue":"2","key":"3049_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10654-020-00677-6","volume":"36","author":"KM Gokhale","year":"2021","unstructured":"Gokhale KM, Chandan JS, Toulis K, Gkoutos G, Tino P, Nirantharakumar K. Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies. Eur J Epidemiol. 2021;36(2):165\u201378.","journal-title":"Eur J Epidemiol"},{"key":"3049_CR20","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE L\u00e9vesque","year":"2010","unstructured":"L\u00e9vesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.","journal-title":"BMJ"},{"issue":"1","key":"3049_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1586\/eci.11.77","volume":"8","author":"A Agrawal","year":"2012","unstructured":"Agrawal A, Sridharan A, Prakash S, Agrawal H. Dendritic cells and aging: consequences for autoimmunity. Expert Rev Clin Immunol. 2012;8(1):73\u201380.","journal-title":"Expert Rev Clin Immunol"},{"key":"3049_CR22","first-page":"251730","volume":"2012","author":"MJ Amador-Patarroyo","year":"2012","unstructured":"Amador-Patarroyo MJ, Rodriguez-Rodriguez A, Montoya-Ortiz G. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis. 2012;2012:251730.","journal-title":"Autoimmune Dis"},{"issue":"5","key":"3049_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0002-9343(94)90173-2","volume":"96","author":"PB Beeson","year":"1994","unstructured":"Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med. 1994;96(5):457\u201362.","journal-title":"Am J Med"},{"issue":"3","key":"3049_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.2353\/ajpath.2008.071008","volume":"173","author":"D Fairweather","year":"2008","unstructured":"Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600\u20139.","journal-title":"Am J Pathol"},{"issue":"6","key":"3049_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.autrev.2013.12.002","volume":"13","author":"OJ Calixto","year":"2014","unstructured":"Calixto OJ, Anaya JM. Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev. 2014;13(6):641\u201354.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"3049_CR26","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","volume":"13","author":"M Versini","year":"2014","unstructured":"Versini M, Jeandel P-Y, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13(9):981\u20131000.","journal-title":"Autoimmun Rev"},{"issue":"11","key":"3049_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/0961203306069344","volume":"15","author":"KH Costenbader","year":"2006","unstructured":"Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006;15(11):737\u201345.","journal-title":"Lupus"},{"issue":"3","key":"3049_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","volume":"2","author":"GS Cooper","year":"2003","unstructured":"Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119\u201325.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"3049_CR29","doi-asserted-by":"publisher","first-page":"A386","DOI":"10.1016\/j.autrev.2011.11.012","volume":"11","author":"L Moroni","year":"2012","unstructured":"Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun Rev. 2012;11(6):A386\u201392.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"3049_CR30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/v11080762","volume":"11","author":"MK Smatti","year":"2019","unstructured":"Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses. 2019;11(8):762.","journal-title":"Viruses"},{"issue":"4","key":"3049_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/1040841X.2019.1614904","volume":"45","author":"HM Hussein","year":"2019","unstructured":"Hussein HM, Rahal EA. The role of viral infections in the development of autoimmune diseases. Crit Rev Microbiol. 2019;45(4):394\u2013412.","journal-title":"Crit Rev Microbiol"},{"issue":"6","key":"3049_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/0961203314523871","volume":"23","author":"S Ara\u00fajo-Fern\u00e1ndez","year":"2014","unstructured":"Ara\u00fajo-Fern\u00e1ndez S, Ahij\u00f3n-Lana M, Isenberg DA. Drug-induced lupus: including anti-tumour necrosis factor and interferon induced. Lupus. 2014;23(6):545\u201353.","journal-title":"Lupus"},{"issue":"5","key":"3049_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2165\/11588500-000000000-00000","volume":"34","author":"C Chang","year":"2011","unstructured":"Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011;34(5):357\u201374.","journal-title":"Drug Saf"},{"key":"3049_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). Obesity: identifying, assessing and managing obesity in adults, young people and children. 2014. https:\/\/www.nice.org.uk\/guidance\/cg189. Accessed 25 Apr 2022"},{"issue":"1","key":"3049_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.dsx.2021.02.009","volume":"15","author":"M Nassar","year":"2021","unstructured":"Nassar M, Nso N, Baraka B, Alfishawy M, Mohamed M, Nyabera A, et al. The association between COVID-19 and type 1 diabetes mellitus: a systematic review. Diabetes Metab Syndr. 2021;15(1):447\u201354.","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"3049_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/08916930701619169","volume":"41","author":"CE Taplin","year":"2008","unstructured":"Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity. 2008;41(1):11\u20138.","journal-title":"Autoimmunity"},{"issue":"4","key":"3049_CR37","doi-asserted-by":"publisher","first-page":"e12945","DOI":"10.1111\/sji.12945","volume":"92","author":"LL ten Bergen","year":"2020","unstructured":"ten Bergen LL, Petrovic A, Aarebrot AK, Appel S. Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol. 2020;92(4):e12945.","journal-title":"Scand J Immunol"},{"issue":"6","key":"3049_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/00054725-200411000-00012","volume":"10","author":"S Joossens","year":"2004","unstructured":"Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M, et al. Pancreatic autoantibodies in inflamm bowel dis. Inflamm Bowel Dis. 2004;10(6):771\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"3049_CR39","unstructured":"Brown J, Kirke-Wade E. Coronavirus: a history of English lockdown laws. London: The Commons Library. 2021. https:\/\/commonslibrary.parliament.uk\/research-briefings\/cbp-9068\/. Accessed 17 Aug 2023."},{"key":"3049_CR40","unstructured":"House of Commons Health and Social Care Committee. Clearing the backlog caused by the pandemic. London: UK Parliament; 2021. https:\/\/committees.parliament.uk\/publications\/8352\/documents\/85020\/default. Accessed 18 Aug 2023"},{"issue":"6","key":"3049_CR41","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1172\/JCI78088","volume":"125","author":"MD Rosenblum","year":"2015","unstructured":"Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228\u201333.","journal-title":"J Clin Invest"},{"key":"3049_CR42","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-022-01909-w","volume":"28","author":"A Subramanian","year":"2022","unstructured":"Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706\u201314.","journal-title":"Nat Med"},{"key":"3049_CR43","unstructured":"UK Health Security Agency. The effectiveness of vaccination against long COVID A rapid evidence briefing. London: UK HSA; 2022. https:\/\/www.icpcovid.com\/sites\/default\/files\/2022-02\/Ep%20241-9%20UK%20Health%20Security%20Agency%20The%20effectiveness%20of%20vaccination%20against%20long%20COVID%20Feb%202022.pdf. Accessed 18 Aug 2023"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-03049-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T19:15:26Z","timestamp":1700594126000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-03049-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3049"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-03049-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.10.06.22280775","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study consists of secondary data analysis of pseudo-anonymised data from the CPRD Aurum database and thus approval was only required to access the database. The project was reviewed and approved by the CPRD Independent Scientific Advisory Committee (study #21_000712) on the 24th of February 2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SH reports receiving funding from NIHR and UKRI. US report no competing interests.\u00a0AS has no declarations during the study period; after the study was completed, she has\u00a0taken a post in AstraZeneca. JL receives grant funding from NIHR, UKRI, Versus Arthritis, The Scar Free Foundation, FOREUM, and Bayer Healthcare for which also she acts as a consultant.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}